Sign up online today & collaborate
or click here to find out more
The rejection of yet another promising cancer drug by NHS cost regulators has sparked a renewed call for reform of the system and the introduction of adaptive licensing to help speed up patient access to innovative medicines.
The National Institute for Health and Care Excellence has today published draft guidelines rejecting the use of Astellas’ Xtandi (enzalutamide) to treat patients with advanced prostate cancer before chemotherapy.
For more click here